GCC Infertility Market

ID: MRFR/HC/43844-HCR
200 Pages
Nidhi Mandole
Last Updated: April 06, 2026
GCC Infertility Market Research Report: Size, Share, Trend Analysis By Sex (Males, Females, Unexplained), By Diagnosis (Men Diagnostic Tests, Women Diagnostic Tests, General Diagnostic Test), By Drugs (Clomiphene Citrate, Letrozole, Serophene, Hormone Treatment, Others) andBy Technology (Assisted Reproductive Technology, Intrauterine Insemination, Surgery) - Growth Outlook & Industry Forecast 2025 To 2035
GCC Infertility Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)12.82%
2024 Market Size$ 50.88 Million
2025 Market Size$ 57.41 Million
2035 Market Size$ 191.79 Million
Key Players
CooperSurgical
Merck KGaA
Ferring Pharmaceuticals
Irvine Scientific
Vitrolife
Reproductive Health Technologies
Trends
  • Technological Advancements in Treatment
  • Increased Awareness and Education
  • Regulatory Support and Policy Changes
Opportunities
  • Rising Infertility Rates
  • Cultural Shifts Towards Family Planning
  • Government Initiatives and Support Programs
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Pharmaceutical, BY Type (USD Million)
      1. 4.1.1 Assisted Reproductive Technology
      2. 4.1.2 Hormone Therapy
      3. 4.1.3 Surgery
      4. 4.1.4 Fertility Preservation
    2. 4.2 Pharmaceutical, BY End User (USD Million)
      1. 4.2.1 Hospitals
      2. 4.2.2 Fertility Clinics
      3. 4.2.3 Home Care Settings
    3. 4.3 Pharmaceutical, BY Gender (USD Million)
      1. 4.3.1 Female
      2. 4.3.2 Male
    4. 4.4 Pharmaceutical, BY Cause of Infertility (USD Million)
      1. 4.4.1 Ovulatory Disorders
      2. 4.4.2 Uterine or Cervical Abnormalities
      3. 4.4.3 Tubal Factors
      4. 4.4.4 Male Factor Infertility
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Pharmaceutical
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 CooperSurgical (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Merck KGaA (DE)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Ferring Pharmaceuticals (CH)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Irvine Scientific (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Vitrolife (SE)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Reproductive Health Technologies (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 OvaScience (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Genea (AU)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 GCC MARKET ANALYSIS BY TYPE
    3. 6.3 GCC MARKET ANALYSIS BY END USER
    4. 6.4 GCC MARKET ANALYSIS BY GENDER
    5. 6.5 GCC MARKET ANALYSIS BY CAUSE OF INFERTILITY
    6. 6.6 KEY BUYING CRITERIA OF PHARMACEUTICAL
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF PHARMACEUTICAL
    9. 6.9 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
    11. 6.11 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
    12. 6.12 PHARMACEUTICAL, BY TYPE, 2024 (% SHARE)
    13. 6.13 PHARMACEUTICAL, BY TYPE, 2024 TO 2035 (USD Million)
    14. 6.14 PHARMACEUTICAL, BY END USER, 2024 (% SHARE)
    15. 6.15 PHARMACEUTICAL, BY END USER, 2024 TO 2035 (USD Million)
    16. 6.16 PHARMACEUTICAL, BY GENDER, 2024 (% SHARE)
    17. 6.17 PHARMACEUTICAL, BY GENDER, 2024 TO 2035 (USD Million)
    18. 6.18 PHARMACEUTICAL, BY CAUSE OF INFERTILITY, 2024 (% SHARE)
    19. 6.19 PHARMACEUTICAL, BY CAUSE OF INFERTILITY, 2024 TO 2035 (USD Million)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 GCC MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.2.2 BY END USER, 2025-2035 (USD Million)
      3. 7.2.3 BY GENDER, 2025-2035 (USD Million)
      4. 7.2.4 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

GCC Infertility Market Segmentation

GCC Infertility Market By Type (USD Million, 2025-2035)

  • Assisted Reproductive Technology
  • Hormone Therapy
  • Surgery
  • Fertility Preservation

GCC Infertility Market By End User (USD Million, 2025-2035)

  • Hospitals
  • Fertility Clinics
  • Home Care Settings

GCC Infertility Market By Gender (USD Million, 2025-2035)

  • Female
  • Male

GCC Infertility Market By Cause of Infertility (USD Million, 2025-2035)

  • Ovulatory Disorders
  • Uterine or Cervical Abnormalities
  • Tubal Factors
  • Male Factor Infertility

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.